Stothers L, Goldenberg S L, Leone E F
Department of Surgery, University of British Columbia, Vancouver, Canada.
J Urol. 1998 Mar;159(3):806-7.
Periurethral collagen injection has been advocated as a safe and effective method of treatment for stress urinary incontinence. This study was conducted to determine the complications associated with transurethral collagen injection for treatment of stress urinary incontinence in women. We report the incidence and management of adverse effects.
A total of 337 women with at least a 1-year history, physical findings and urodynamic abnormalities consistent with stress urinary incontinence, who required pads or protective clothing, and who had no or only grade 1 cystocele were enrolled in this prospective cohort study. A third party documented adverse effects at each followup.
De novo urinary urgency with incontinence was the most frequent and serious complication, occurring in 12.6% of patients, and in many the symptoms were irreversible. Hematuria (5% of patients) and urinary retention (1.9%) were short-lived and resolved spontaneously. Delayed reaction at the skin test site occurred in 0.9% of the patients (3) and was associated with arthralgias in 2.
Contrary to previous reports that periurethral collagen injection is complication-free, we found an overall incidence of 20% risk of complications in any given individual.
尿道周围胶原注射已被提倡作为治疗压力性尿失禁的一种安全有效的方法。本研究旨在确定经尿道胶原注射治疗女性压力性尿失禁相关的并发症。我们报告了不良反应的发生率及处理情况。
共有337名女性纳入这项前瞻性队列研究，她们至少有1年的病史，体格检查和尿动力学异常符合压力性尿失禁，需要使用尿垫或防护服，且无或仅有1级膀胱膨出。每次随访时由第三方记录不良反应。
新发伴尿失禁的尿急是最常见且最严重的并发症，12.6%的患者出现该并发症，且许多患者的症状不可逆。血尿（5%的患者）和尿潴留（1.9%）持续时间短且可自发缓解。0.9%的患者（3例）在皮肤试验部位出现延迟反应，其中2例伴有关节痛。
与先前报道的尿道周围胶原注射无并发症不同，我们发现任何个体发生并发症的总体风险发生率为20%。
